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Introduction 100
In 60% of cases, patients with hepatocellular carcinoma (HCC) are diagnosed 101 when tumors are no longer eligible for potentially curative therapies [1] . In this setting, only 102 two treatments have been included in guidelines after demonstrating survival advantages in 103 randomized controlled trials.
Patients at an intermediate stage benefit 104 from chemoembolization and have an estimated median overall survival (OS) of 105 26 months [2] , while at advanced stages, sorafenib extends survival from 8 to almost 106 11 months [3] . 107
The optimal management of HCC requires an early and accurate assessment of tumor 108 response to therapy, particularly for those patients who experience toxicity [1] . Nevertheless, 109
traditionally established response criteria based on size for tumor burden, as defined by 110
World Health Organization (WHO) criteria or the Response Evaluation Criteria in Solid 111
Tumors (RECIST), have been challenged in HCC due to the nature of effective treatments. 112
Both chemoembolization and sorafenib often induce direct tumor necrosis without critically 113 affecting tumor size [4] . Moreover, valid radiological criteria are crucial for the optimal 114 development of clinical trials testing new therapies for HCC: although the primary goal is to 115 prolong survival, alternative end-points evaluating disease response and progression have 116 been used to assess treatment effectiveness earlier and reduce drug development costs [5] . 117
In addition, controversy remains on what should be an ideal surrogate end-point in HCC 118 research. Objective response was considered an adequate surrogate end-point when 119 assessing benefits of loco-regional therapies [2, 6] by European Society for the Study of the 120 Liver (EASL) criteria [7] . These criteria were proposed in 2000 by a panel of experts as an 121 amendment to WHO criteria, considering treatment-induced tumor necrosis and the concept 122 of viable tumor assessment. However, the standardization of RECIST in trials evaluating 123 oncologic therapies led to adopting these criteria for the first time in HCC in the SHARP 124 trial [3] . This landmark trial demonstrated that sorafenib was able to significantly increase 125 OS compared to placebo, despite an objective response rate (ORR) of just 2%. 126
Subsequently, experts convened by the American Association for the Study of Liver 127
Diseases (AASLD) developed a set of guidelines that aimed to provide a common 128 conceptual framework for the design of clinical trials in HCC and endorsed time to 129 progression (TTP) as the optimal secondary end-point in 2008 [5] . At the same time, this 130 provided the basis of the modification of RECIST criteria (mRECIST) [8] . These criteria 131 incorporate the concept of viable tumor assessment, defined as the portions of tumor 132
showing arterial enhancement, and thus providing improved sensitivity for clinical 133 assessment. Moreover, mRECIST also incorporates novel concepts in assessing 134 progression with lymph node involvement, ascites and development of 135 new lesions [5, 8] (Fig. 1 ). Thus, assessment of response by mRECIST was thereafter 136 endorsed by the EASL clinical practice guidelines of management of HCC [1] . 137
Several studies and one meta-analysis have shown a correlation between objective 138 response by mRECIST and survival in patients treated with loco-regional therapies [9] [10] [11] [12] [13] . In 139 advanced HCC cases treated with systemic targeted therapies, few studies suggest a 140 prognostic value of objective response by mRECIST [14] [15] [16] [17] . However, their retrospective 141 nature and the absence of a time-dependent multivariate analysis considering immortal time 142 bias, limit the level of evidence in this setting. 143
We performed an individual patient data analysis of BRISK-PS, a phase III trial comparing 144 brivanib and placebo in the second line setting that was the first to prospectively incorporate 145 mRECIST for the assessment of treatment benefit [18] . The aim was to investigate whether 146 objective response by mRECIST could accurately predict OS in patients with advanced HCC 147 treated by systemic therapies. The primary end-point of OS was defined as the time from random assignmentuntil death as 171 a result of any cause. Secondary end-points were TTP and ORR. TTP was defined as the 172 time from random assignment to radiologic disease progression and ORR as the percentage 173 of patients with complete response (CR) or partial response (PR). Tumor measurements 174 were performed every 6 weeks during treatment by contrast-enhanced, computed 175 tomography or magnetic resonance imaging. To define objective response, confirmatory 176 assessments were performed ⩾28 days after the initial demonstration of the response. Assessment was performed by a blinded independent radiologic committee using mRECIST. 178
Results of TTP and ORR were based on central review. Briefly, the study images were 179 subjected to quality control (adherence to image acquisition guidelines and trial protocol) 180 before they were evaluated by two board-certified radiologists with specific expertise in liver 181
imaging. If there was disagreement between the two reviewers in the response assessment 182 at any time point, a third adjudicating radiologist reviewed the case and decided which of the 183 two primary radiologists should be agreed with. In this regard, a previous study showed up 184 to 73% of inter-reader agreement for mRECIST in HCC patients treated with sorafenib and a 185 comparable weighted k coefficient to RECIST [15] . 186
Overall, 226 of 263 brivanib patients (85.9%) and 108 of 132 placebo patients (81.8%) were 187 evaluable for response because of the presence of baseline and at least one on-study scan. 188
Of the 61 patients not evaluable due to discontinuation of treatment before the first 189 radiological assessment, 27 survived less than 6 weeks. where the variable changed [19, 20] . The relationship between probability of survival in 206 deciles and log (odds) (i.e., log [p/1 − p] where p is the prevalence of the end-point) for ORR 207 was evaluated using Pearson's correlation coefficient and linear regression; the 95% CI for 208 the R were estimated by bootstrap with 10,000 simulations. The same approach was used to 209 evaluate the association between log HRs for OS and log odds ratios for ORR after dividing 210 the trial into five subgroups at random. All statistical tests were two-tailed and the threshold 211 level of significance was 0.05. 212
Results 215

Objective response by mRECIST as an independent prognostic factor 216
At the end of follow-up, 233 of the 334 patients with evaluable response had died, with a 217 median OS of 10.1 months (95% CI; 8.6-11.6) and 9.5 (95% CI; 7.4-11.7) for brivanib and 218 placebo groups respectively. There were no statistically significant differences between 219 treatments (HR = 0.88; 95% CI, 0.67-1.16, p = 0.358), as observed in the whole BRISK-PS 220 population (HR = 0.89; 95.8% CI, 0.69-1.15, p = 0.331). 221
There was no CR in either of the two arms among patients evaluated. ORR was 11.5% 222 (n = 26/226) with brivanib and 1.9% (n = 2/108) with placebo. Overall, considering all 223 patients assessed, those patients achieving objective response (n = 28) had a median OS 224
as per landmark analysis of 15.0 months (95% CI; 13.7-16.3), significantly better than the 225 9.4 (95% CI; 8.2-10.6) months of patients without objective response (n = 306) (HR = 0.28; 226 95%CI 0.14-0.54, p <0.001) ( Fig. 2A) . Specifically, for patients in the brivanib arm, those 227 with objective response had better survival (14.3 vs. 9.4 months, HR = 0.31; 95%CI 0.16-228 0.60, p <0.001) (Fig. 2B) . 229
In order to evaluate objective response as a predictor of OS we used a Cox model with 230 objective response as a time-dependent variable, since this variable was measured after 231 entry into the study. Multivariate analysis irrespective of treatment identified objective 232 response by mRECIST as an independent prognostic factor of OS (HR = 0.48; 95% CI, 233 0.26-0.91, p = 0.025) along with nodal metastasis, distant metastasis, macrovascular 234 invasion, AFP >200 ng/ml, albumin > median and bilirubin > median (Table 1) . Objective 235 response maintained independent prognostic value in patients treated with brivanib 236 (HR = 0.50; 95% CI, 0.25-099, p = 0.047) ( Baseline demographics and disease characteristics that significantly influenced obtaining a 240 higher percentage of objective response by mRECIST after treatment with brivanib were: 241 BCLC A/B stage, absence of distant metastasis and the presence of low and high levels of 242 AFP and albumin, respectively (Table 3) . 243
Objective response by mRECIST as a surrogate end-point 244
To further explore the impact of objective response by mRECIST in the assessment of 245 efficacy of a systemic molecular targeted therapy, we performed a Pearson correlation 246 between the raw survival probability of patients in deciles and the log odds ratios of ORR. 247
This method allowed the determination of the ORR observed in each one of the ten 248 subgroups, sorted by worse to better outcome, and their association. As shown in Fig. 3 , 249 treatment effects on ORR and OS were significantly associated (R = −0.92; 95% CI, −1 to 250 −0.73, p <0.001). 251
In order to provide additional surrogacy of end-points, a proper correlation between the 252 treatment effect on the surrogate outcome (objective response by mRECIST) and the 253 treatment effect on the clinical outcome (OS) is required. To attempt this, we split the cases 254 in five random subgroups of equal size (395/5 = 79). The association between log HRs for 255 OS and log odds ratios for ORR was high (R = −0.80; 95% CI, −1 to 0.23, p = 0.091) ( Fig.  256   4) . 257
Of note, median time to objective response was 1.4 months (range: 0.7-8.4) in the 26 258 patients that reached a PR with brivanib. This means that the first radiological evaluation, 259 conducted at 6 weeks, detects the majority of patients responding to treatment and thus, 260 objective response could be considered an early surrogate end-point. 261
Discussion 262
OS remains as the main primary end-point in clinical research in oncology and in HCC. 263
However, there is a need to identify a reliable secondary end-point able to recapitulate OS. 264
This will allow ineffective drugs in phase II trials to be discarded, and enable testing new 265 therapies in phase III, where median survivals of patients with intermediate HCC might 266 exceed 30 months, and cross over treatments might dilute the potential benefits during 267 follow-up. Objective response was previously considered a reliable surrogate end-point for 268 loco-regional therapies in HCC [7] , but studies assessing response by RECIST criteria failed 269 to capture this benefit. At advanced stages of the disease, performance of objective 270 response by RECIST was disappointing in capturing benefits of sorafenib therapy [3] . As a 271 consequence of these failures, two strategies emerged: a) assess response according to the 272 'hallmarks of HCC' for defining viable tumors (mRECIST criteria) [5, 8] , b) endorse TTP as a 273 more adequate surrogate end-point, as per the SHARP trial results [5] . 274
The present study defines objective response as an independent prognostic factor for OS, 275
and as a potentially reliable surrogate end-point. First, we established an 11.5% ORR by 276 mRECIST in patients treated with brivanib in the setting of BRISK-PS trial. This figure  277 compares well with data from a phase III trial of brivanib in front-line advanced HCC, where 278 an ORR of 12% in those 577 patients randomized to brivanib arm was reported [21] . 279 Furthermore, in this study, ORR for sorafenib was 9%, which is within the range of 9-28% 280 described in several retrospective studies [14] [15] [16] [17] 22, 23] . These figures for sorafenib are far 281 from the 2% ORR described for RECIST [5] . Thus, assessment of mRECIST in patients with 282 advanced HCC treated with anti-angiogenic drugs, might be in line with other alternative 283 criteria developed to measure response in other solid tumors. This is the case for Choi 284 criteria, for the measurement of response in gastrointestinal stromal tumors treated 285 with imatinib [24] or immune-related response criteria for melanomas treated with checkpoint 286 inhibitors [25] . 287 Second, we sought to define if objective response was an independent predictor of OS in 288 advanced HCC. For this purpose, we performed a multivariate time-dependent analysis that 289 defined several variables related to tumoral status (macrovascular invasion, metastases, 290 AFP >200 ng/ml), liver function (bilirubin, albumin) and treatment response measured by 291 mRECIST as independent predictors for survival. This result is critical, since it represents 292 the first requirement to propose ORR as surrogate end-point for OS in advanced HCC. In 293 addition, the level of evidence is high due to the phase III randomized controlled nature of 294 the original study. 295
Finally, we aimed to explore if ORR could be used as a potential surrogate end-point in 296
HCC. The way to evaluate therapeutic effectiveness in oncology is based upon a statistically 297 significant and clinically meaningful improvement in OS [26] . In clinical research, surrogate 298 end-points are used in order to provide earlier measures of difference in treatment effect 299 than OS [1, 27] . In our study, we identified a significant correlation between ORR assessed 300 by mRECIST after brivanib and OS (R = −0.92). Notably, most patients with objective 301 response could be identified in the first radiological evaluation conducted at 6 weeks. 302
Moreover, objective response overcomes a limitation of other end-points that include 303 disease stabilization in their definitions (disease control rate, TTP or progression-free 304 survival [PFS]) since these end-points may be influenced by the inherent speed of 305 progression of tumors independently of the effect of the drug [28] . This makes objective 306 response by mRECIST a promising surrogate end-point to evaluate efficacy (if a treatment is 307 effective for a certain condition) after a phase II trial, and thus to decide its further 308
development. 309
Thus, if ORR is an independent predictor of survival and a potentially good surrogate of OS, 310
we need to explain how the differences in ORR between brivanib and placebo arms (Odds 311 ratio 5.72; 95% CI, 1.41-23.25, p = 0.003) were unable to correlate with the lack of survival 312 differences in this trial. The most obvious explanation is that the magnitude of the benefit 313 obtained by a drug certainly depends on the type of ORR benefit (CR vs. PR) and the 314 toxicity. The ORR obtained in the trial according to intention to treat for the brivanib arm was 315 9.9% (26/263), a figure that is suboptimal to impact on the final OS result. Other effective 316 drugs in cancer such as crizotinib, which achieved a 29% absolute increase in ORR 317 compared to chemotherapy (74% vs. 45%) in non-small cell lung cancer [29] , or nivolumab, 318 which achieved 40% ORR in melanoma patients, but with a high rate of complete 319 responses [30] , are examples defining a threshold for ORR to directly impact in OS benefit. 320 Therefore, to reliably predict differences among treatments, a higher magnitude of the 321 difference in terms of quantity (percentage of objective response) and quality (presence of 322
CRs or long-lasting responses) would be necessary. This concept is particularly challenging 323 in the HCC field since, unlike other tumors, the post-progression time is generally longer 324 than TTP and may dilute part of the benefit produced by the drug during treatment [18, 31] . 325
The importance of objective response as a surrogate end-point in cancer trials has been 326 acknowledged in some papers by regulatory agencies and used in breakthrough trials [32] . 327
Indeed, 24 of the 25 FDA accelerated marketing approvals for oncologic indications between 328
2009 and 2014 were based on ORR [33] . This point is of significance since the last 329 randomized studies conducted in HCC have shown inconsistencies between TTP and 330 OS [34] . In this sense, for instance, the two positive trials showed similar OS rates for 331 sorafenib in front-line and regorafenib in second line but with clearly distinct TTP 332
figures [3, 35] . Thus, TTP is currently re-visited as a surrogate end-point in trial design for 333 advanced HCC. In order to provide absolutely robust data to enforce recommendations in 334 guidelines, the definitive evidence will be obtained when several randomized trials following 335 mRECIST assessment will be available, allowing this a meta-analysis approach comparing 336 the Pearson correlation coefficient of ORR, TTP or other surrogate end-points with OS [36-337 40] . 338
In conclusion, these results provide high-level evidence, suggesting that radiological 339 response in advanced HCC by mRECIST captures clinically meaningful outcomes in terms 340 of OS and therefore, if confirmed in other future studies at individual and trial-level [36] [37] [38] [39] [40] Internal and external 95% CI bands identify the uncertainty for expected value of the dependent variable and for the individual predicted value, respectively. Deciles of Survival Probability=-1.293-2.261*logOdds(ORR).
Figure legends
Fig. 4. Correlation between HR for OS and odds ratio for ORR in five random subsamples of patients within BRISK-PS. The central regression line is their association.
Internal and external 95% CI bands identify the uncertainty for expected value of the dependent variable and for the individual predicted value, respectively. ln(HR for OS)=0.621 -1.139*ln(Odds Ratio for ORR).
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